VKTX · Viking Therapeutics, Inc.
$35.39
-1.74% last session
End-of-day data · updated 2026-07-25
Market cap
$4B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-7.6
Dividend yield
—
Beta
0.66
Avg volume
2M
Employees
0K
2D change
-1.70%
5D change
-4.37%
10D change
-7.99%
30D change
-5.95%
60D change
12.95%
MTD change
-7.18%
YTD change
-1.11%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — VKTX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-28
Latest call per bank · past 12 months
JP Morgan
Overweight$75.00
+111.9% vs priceMorgan Stanley
Overweight$102
+188.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-28 | Lake Street | Initiates | Buy | $0.00 → $89.00 |
| 2026-05-01 | BTIG | Reiterates | Buy | $125 |
| 2026-04-30 | Cantor Fitzgerald | Maintains | Overweight | $105 → $100 |
| 2026-03-23 | HC Wainwright & Co. | Reiterates | Buy | $102 |
| 2025-11-12 | Canaccord Genuity | Maintains | Buy | $106 → $107 |
| 2025-10-29 | Canaccord Genuity | Initiates | Buy | $0.00 → $106 |
| 2025-10-24 | JP Morgan | Maintains | Overweight | $80.00 → $75.00 |
| 2025-10-23 | Morgan Stanley | Maintains | Overweight | $98.00 → $102 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-27
- RSI (14): RSI is 45 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 3.2% above the 50-day MA ($33.69).
- Price vs 200-day MA: Trading 2.9% above the 200-day MA ($33.79).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.66) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($23.09) and high ($42.13).
VKTX Price Chart
Loading chart for VKTX…
Fundamentals
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$121B 5.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$69B -14.8% YTD
ARGX
argenx SE
$57B 9.2% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.6% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -31.7% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.7% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.